About Alto Neuroscience
Alto Neuroscience is a company based in San Francisco (United States) founded in 2019 by Amit Etkin.. Alto Neuroscience has raised $144.72 million across 9 funding rounds from investors including Lilly, Novartis and ARE. The company has 76 employees as of December 31, 2024. Alto Neuroscience offers products and services including Drug Candidates and Precision Approach Platform. Alto Neuroscience operates in a competitive market with competitors including Supernus Pharmaceuticals, Newron Pharmaceuticals, Reunion Neuroscience, Cerecor and Neurovance, among others.
- Headquarter San Francisco, United States
- Employees 76 as on 31 Dec, 2024
- Founders Amit Etkin
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Alto Neuroscience, Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-61.43 M-69.21as on Dec 31, 2024
-
EBITDA
$-68.11 M-81.93as on Dec 31, 2024
-
Total Equity Funding
$144.72 M (USD)
in 9 rounds
-
Latest Funding Round
$50 M (USD), Post-IPO
Oct 21, 2025
-
Investors
Lilly
& 21 more
-
Employee Count
76
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Alto Neuroscience
Alto Neuroscience is a publicly listed company on the NYSE with ticker symbol ANRO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Alto Neuroscience
Alto Neuroscience offers a comprehensive portfolio of products and services, including Drug Candidates and Precision Approach Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Biology-driven medicines targeting neuropsychiatric disorders
System for predicting clinical responses in mental health treatments
Unlock access to complete
Unlock access to complete
Funding Insights of Alto Neuroscience
Alto Neuroscience has successfully raised a total of $144.72M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $50 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 9
- Last Round Post-IPO — $50.0M
-
First Round
First Round
(13 Sep 2019)
- Investors Count 22
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2025 | Amount | Post-IPO - Alto Neuroscience | Valuation |
investors |
|
| Nov, 2023 | Amount | Series C - Alto Neuroscience | Valuation | InVivium Capital | |
| Jan, 2023 | Amount | Series B - Alto Neuroscience | Valuation | Alpha Wave Global |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Alto Neuroscience
Alto Neuroscience has secured backing from 22 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Lilly, Novartis and ARE. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
InVivium Capital is focused on healthcare and life sciences investments.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
VC fund focused on equity markets
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Alto Neuroscience
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Alto Neuroscience
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Alto Neuroscience Comparisons
Competitors of Alto Neuroscience
Alto Neuroscience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Supernus Pharmaceuticals, Newron Pharmaceuticals, Reunion Neuroscience, Cerecor and Neurovance, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Specialty pharmaceutical products for CNS diseases are developed and commercialized.
|
|
| domain | founded_year | HQ Location |
Therapies for central nervous system diseases and pain are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for mental health conditions are developed using serotonergic psychedelics.
|
|
| domain | founded_year | HQ Location |
Therapeutics for immunological and neurological disorders are developed.
|
|
| domain | founded_year | HQ Location |
Neurochemical modulators for ADHD treatment are developed by Neurovance.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Alto Neuroscience
Frequently Asked Questions about Alto Neuroscience
When was Alto Neuroscience founded?
Alto Neuroscience was founded in 2019.
Where is Alto Neuroscience located?
Alto Neuroscience is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Who is the current CEO of Alto Neuroscience?
Amit Etkin is the current CEO of Alto Neuroscience. They have also founded this company.
Is Alto Neuroscience a funded company?
Alto Neuroscience is a funded company, having raised a total of $144.72M across 9 funding rounds to date. The company's 1st funding round was a Series B of $25M, raised on Sep 13, 2019.
How many employees does Alto Neuroscience have?
As of Dec 31, 2024, the latest employee count at Alto Neuroscience is 76.
What does Alto Neuroscience do?
Founded in 2019 and based in San Francisco, United States, Alto Neuroscience operates in the biotechnology sector with an AI platform focused on neurological and psychiatric conditions. Biomarkers such as EEG, wearable data, behavioral patterns, and genetics are analyzed to develop personalized drugs. A pipeline includes ALTO-100 for depression and ALTO-101 for neurodegenerative diseases, supporting targeted treatments.
Who are the top competitors of Alto Neuroscience?
Alto Neuroscience's top competitors include Supernus Pharmaceuticals, Newron Pharmaceuticals and Seaport Therapeutics.
What products or services does Alto Neuroscience offer?
Alto Neuroscience offers Drug Candidates and Precision Approach Platform.
Is Alto Neuroscience publicly traded?
Yes, Alto Neuroscience is publicly traded on NYSE under the ticker symbol ANRO.
Who are Alto Neuroscience's investors?
Alto Neuroscience has 22 investors. Key investors include Lilly, Novartis, ARE, HHS, and Alkeon Capital Management.
What is Alto Neuroscience's ticker symbol?
The ticker symbol of Alto Neuroscience is ANRO on NYSE.